fbpx

BD acquires UK surgical sealant maker

Jeffrey Kanige//December 9, 2021//

BD acquires UK surgical sealant maker

Jeffrey Kanige//December 9, 2021//

Listen to this article

BD said Dec. 9 that it acquired Tissuemed Ltd., a manufacturer of self-adhesive surgical sealant films based in Leeds, England.

The target’s lead product, Tissuepatch, bonds with tissue to help control internal bleeding or prevent leaks from surgical incisions. BD said the technology is thin, flexible, transparent and ready to use out of the package for a variety of surgical applications.

“This advanced sealant serves as a strategic complement to the BD products used in the operating room today — providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions,” said Kevin Kelly, BD’s president of Surgery, in a statement. “Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries.”

The buyer said the deal expands its offerings for surgeons outside the U.S. and leverage its reach and expertise to innovate within the sealant technology category. Franklin Lakes-based BD added that it expects the category to grow significantly over the next five to 10 years.

Terms of the deal, which BD said would be immaterial to its fiscal 2022 results, were not disclosed.

BD has been active on the deal-making front in recent weeks. On Dec. 2. the company said it acquired Venclose Inc., which has developed a treatment of chronic venous insufficiency, a disease caused by malfunctioning valves.

And on Dec. 6, BD revealed the name — embecta — and leadership of  its Diabetes Care business, which is being spun off as a separate publicly traded company. The spinoff is expected to close in the first quarter of 2022.